The drug development company Arexis AB announced today that it has received a European patent covering the skeletal muscle specific γ3 subunit of AMPK, representing an important part of Arexis’ patent portfolio in the AMPK field. Arexis is currently developing a novel oral therapy based on a non-insulin dependent mechanism for type II diabetes, with AMPK as target.
The granted patent – ‘Variants of the gamma chain of AMPK, DNA sequences encoding the same, and uses thereof’ – covers the skeletal muscle specific γ3 subunit of AMPK (Adenosine 5´monophosphate-activated protein kinase). It will play an important role in Arexis’ AMPK patent portfolio, which forms an umbrella under which further R&D relating to the function of AMPK, and especially the muscle specific γ3 subunit, can be performed. Even more importantly, this umbrella gives Arexis the unique and exclusive possibility to develop compounds that have specificity only for the γ3 subunit of AMPK, which is expected to offer the...